EBRT causes rectal toxicity in up to 35% of treated patients

External Beam Radiation Therapy (EBRT) is the treatment of choice for patients with localized prostate cancer; however it has limitations and complications.

Recent technological advancements enable the use of higher and thus more effective and more accurate radiation doses to the tumor. Modern radiation therapy such as Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT) improve treatment accuracy and effectiveness, however parts of the ventral rectal wall are still frequently exposed to high radiation doses resulting in rectal toxicity. Grade 2 (G2) acute proctitis occurs in up to 35% of treated patients.

With the BioProtect Balloon Implant, safe dose escalation and hypofractionation are finally a reality!

Hypofractionation could alter the management of localized prostate cancer. Hypofractionation involves a reduction in the number of daily fractions (from over 40 to less than 20) while increasing the daily dose. Dose escalation can limit cancer recurrence and improve overall treatment success, as documented in many clinical studies.

The higher the dose, the more effective the treatment:

Since prostate cancer is highly sensitive to fraction size, hypofractionation could easily become the standard of care in radiation therapy, making external beam radiation therapy a much more cost- effective and attractive treatment modality, with a profound impact on patients’ quality of life.

Nevertheless, an increase in daily dose, though very effective, may cause even more extensive damage to surrounding healthy tissue.

When using a higher radiation dose, the need for a separator that shifts the rectum away from harmful radiation is paramount. With such a device, safe dose escalation and hypofractionation are feasible.

The BioProtect Balloon Implant enables dose escalation and hypofractionation, enabling a more effective therapy while bringing proctitis-related complications to a minimum.